---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003420"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:46:17.817480+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%

## Summary
- Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).
- Julie Andrews named CFO, effective Jan 15; base salary $475K, target bonus 70%, sign-on equity $1.8M.
- Kevin Kenny departed as officer Jan 8; eligible for severance and $500/hr consulting for 12 months.
- Q4 preliminary net sales $200.3M, +63.8% reported (+7.5% pro forma); BGT up 15.3%.
- Full-year 2023 net sales $746.5M, +62% reported (+6.5% pro forma).

## SEC filing metadata
- accession: 0000950170-24-003420
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/ofix-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003420
- JSON: https://secwatch.observer/filing/0000950170-24-003420.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003420.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the fiscal quarter and year ended December 31, 2023 results: revenue $200.3 million.
  - Period: the fiscal quarter and year ended December 31, 2023
  - Revenue: $200.3 million
  - Result: preliminary results
  source text: Net sales of $200.3 million, an increase of 64% on a reported basis and an increase of 8% on a pro forma basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm
- Executive change
  Julie Andrews was appointed as Chief Financial Officer at Orthofix Medical Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm
- Executive change
  Massimo Calafiore was appointed as President and Chief Executive Officer at Orthofix Medical Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.